Association between Mutations in Papain-like Protease (PLpro) of SARS-CoV-2 with COVID-19 Clinical Outcomes

被引:4
|
作者
Tan, Jinlin [1 ]
Wu, Zhilong [2 ]
Hu, Peipei [3 ]
Gan, Lin [4 ]
Wang, Ying [1 ]
Zhang, Dingmei [1 ,5 ]
机构
[1] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou 510080, Peoples R China
[2] Fourth Peoples Hosp Foshan City, Foshan 528000, Peoples R China
[3] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China
[4] Huangpu Dist Ctr Dis Control & Prevent, Guangzhou 510700, Peoples R China
[5] NMPA Key Lab Qual Monitoring & Evaluat Vaccines &, Guangzhou 510080, Peoples R China
来源
PATHOGENS | 2022年 / 11卷 / 09期
关键词
SARS-CoV-2; PLpro; COVID-19; mutation; outcome; INSIGHTS;
D O I
10.3390/pathogens11091008
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Papain-like protease (PLpro) is important for the replication and transcription of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to reveal the PLpro mutations associated with the clinical outcomes of patients. Due to the importance of the S protein in the pathogenicity of SARS-CoV-2, the mutation of the S protein was also analyzed in this study. After downloading the data from the Global Initiative on Sharing Avian Influenza Data (GISAID) database, samples were divided into two groups on the basis of patient status, namely, recovered and dead groups. This study performed a univariate analysis and further explored the association of mutations with patient outcomes through multivariate logistic regression analysis. A total of 138,492 samples were used for analysis. The patients had a mean age of 43.66 +/- 21.56 years, and 51.3% of them were female. Multivariate logistic regression results showed that, compared with men, women had a lower risk of dying from coronavirus disease 2019 (COVID-19) (OR = 0.687, 95%CI: 0.638-0.740). Compared with patients aged 17 years and younger, patients aged 18-64 years (OR = 2.864, 95%CI: 1.982-4.139) and patients over 65 years old (OR = 19.135, 95%CI: 13.280-27.572) had a higher risk of death after infection. Compared with the wild type, P78L (OR = 5.185, 95%CI: 2.763-9.730) and K233Q (OR = 5.154, 95%CI: 1.442-18.416) in PLpro were associated with an increased risk of death. A synergistic interaction existed between age and mutations A146D and P78L. The results of the multivariate logistic regression analysis of the data on vaccinated patients demonstrated that, compared with the wild type, the P78L (OR = 3.376, 95%CI: 2.040-5.585) mutation was associated with an increased risk of death. In conclusion, compared with the wild-type PLpro protein, the P78L and K233Q mutations may increase the risk of death in infected individuals. In addition, a synergistic effect existed between age and P78L and K233Q that increased the risk of death in older patients.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Inhibitor induced conformational changes in SARS-COV-2 papain-like protease
    Glaucio Monteiro Ferreira
    Thanigaimalai Pillaiyar
    Mario Hiroyuki Hirata
    Antti Poso
    Thales Kronenberger
    Scientific Reports, 12
  • [32] Development of a Fluorescence Polarization Assay for the SARS-CoV-2 Papain-like Protease
    Li, Kan
    Jadhav, Prakash
    Wen, Yu
    Tan, Haozhou
    Wang, Jun
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2025,
  • [33] Inhibitor induced conformational changes in SARS-COV-2 papain-like protease
    Ferreira, Glaucio Monteiro
    Pillaiyar, Thanigaimalai
    Hirata, Mario Hiroyuki
    Poso, Antti
    Kronenberger, Thales
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [34] Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?
    Maiti, Biplab K.
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2020, 3 (05) : 1017 - 1019
  • [35] In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease
    Huynh, Tien
    Cornell, Wendy
    Luan, Binquan
    FRONTIERS IN CHEMISTRY, 2021, 8
  • [36] SARS-COV-2 Coronavirus Papain-like Protease PLpro as an Antiviral Target for Inhibitors of Active Site and Protein–Protein Interactions
    Ershov P.V.
    Yablokov E.O.
    Mezentsev Y.V.
    Chuev G.N.
    Fedotova M.V.
    Kruchinin S.E.
    Ivanov A.S.
    Biophysics, 2022, 67 (6) : 902 - 912
  • [37] A Patent Review on SARS Coronavirus Papain-Like Protease (PLpro) Inhibitors
    Chia, C. S. Brian
    Lim, Siew Pheng
    CHEMMEDCHEM, 2023, 18 (16)
  • [38] In Silico Identification of Inhibitory Compounds for SARS-Cov-2 Papain-Like Protease
    Miwa, Kazunori
    Guo, Yan
    Hata, Masayuki
    Hirano, Yoshinori
    Yamamoto, Norio
    Hoshino, Tyuji
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2023, 71 (12) : 897 - 905
  • [39] Development of a Fluorescence Polarization Assay for the SARS-CoV-2 Papain-like Protease
    Li, Kan
    Jadhav, Prakash
    Wen, Yu
    Tan, Haozhou
    Wang, Jun
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2025, 8 (03) : 774 - 784
  • [40] Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease
    Qiao, Huarui
    Li, Lingyun
    Wang, Lu
    Yu, Haijun
    Hu, Fangzheng
    Zhou, Xin
    Yang, Hongzhao
    Xu, Jianfeng
    Meng, Xiangjing
    Geng, Yong
    Dai, Yuanyuan
    PROTEIN EXPRESSION AND PURIFICATION, 2023, 207